Strong inhibition of Celastrol towards UDP-glucuronosyl transferase (UGT) 1A6 and 2B7 indicating potential risk of UGT-based herb-drug interaction

Molecules

Volumn 17, Issue 6, 2012, Pages 6832-6839

  Zhang, Yong Sheng ^a   Tu, Yan Yang ^a   Gao, Xing Chun ^a   Yuan, Jun ^a   Li, Gang ^a   Wang, Liang ^a   Deng, Jian Ping ^a   Wang, Qi ^a   Ma, Ru Meng ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Celastrol; Herb drug interaction; UDP glucuronosyltransferase (UGT)

Indexed keywords

4-METHYLUMBELLIFERONE; DRUG DERIVATIVE; ENZYME INHIBITOR; GLUCURONOSYLTRANSFERASE; HYMECROMONE; TRIPTERINE; TRITERPENE; UDP GLUCURONOSYLTRANSFERASE, UGT1A6; UDP-GLUCURONOSYLTRANSFERASE, UGT1A6; UGT2B7 PROTEIN, HUMAN;

ARTICLE; CHEMISTRY; DRUG ANTAGONISM; HERB DRUG INTERACTION; HUMAN; KINETICS; METABOLISM; TRIPTERYGIUM;

ENZYME INHIBITORS; GLUCURONOSYLTRANSFERASE; HERB-DRUG INTERACTIONS; HUMANS; HYMECROMONE; KINETICS; TRIPTERYGIUM; TRITERPENES;

EID: 84862980316     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules17066840     Document Type: Article

References (26)

1. Setty, A. R.; Sigal, L. H. Herbal medications commonly used in the practice of rheumatology: Mechanisms of action, efficacy, and side effects. Semin. Arthritis Rheum. 2005, 34, 773-784. (Pubitemid 40732452)
2. Zhu, H.; Liu, X. W.; Cai, T. Y.; Cao, J.; Tu, C. X.; Lu, W.; He, Q. J.; Yang, B. Celastrol acts as a potent antimetastatic agent targeting β1 integrin and inhibiting cell-extracellular matrix adhesion, in part via the p38 mitogen-activated protein kinase pathway. J. Pharmacol. Exp. Ther. 2010, 334, 489-499.
3. Tao, X.; Younger, J.; Fan, F. Z.; Wang, B.; Lipsky, P. E. Benefit of an extract of Tripterygium wilfordii Hook F in patients with rheumatoid arthritis: A double-blind, placebocontrolled study. Arthritis Rheum. 2002, 46, 735-743.
4. Pinna, G. F.; Fiorucci, M.; Reimund, J. M.; Taquet, N.; Arondel, Y.; Muller, C. D. Celastrol inhibits pro-inflammatory cytokine secretion in Crohn's disease biopsies. Biochem. Biophys. Res. Commun. 2004, 322, 778-786. (Pubitemid 39164421)
5. Cleren, C.; Calingasan, N. Y.; Chen, J.; Beal, M. F. Celastrol protects against MPTP-and 3-nitropropionic acidinduced neurotoxicity. J. Neurochem. 2005, 94, 995-1004. (Pubitemid 41170587)
6. Allison, A. C.; Cacabelos, R.; Lombardi, V. R.; Alvarez, X. A.; Vigo, C. Celastrol, a potent antioxidant and antiinflammatory drug, as a possible treatment for Alzheimer's disease. Prog. Neuropsychopharmacol. Biol. Psychiatry 2001, 25, 1341-1357. (Pubitemid 33022713)
7. Huang, Y. L.; Zhou, Y. X.; Fan, K. S.; Zhou, D. Celastrol inhibits the growth of human glioma xenografts in nude mice through suppressing VEGFR expression. Cancer Lett. 2008, 264, 101-106.
8. Dai, Y.; DeSano, J.; Tang, W. H.; Meng, X. J.; Meng, Y.; Burstein, E.; Lawrence, T. S.; Xu, L. A. Natural proteasome inhibitor celastrol suppresses androgen-independent prostate cancer progression by modulating apoptotic proteins and NF-kappaB. PLoS One 2010, 5, e14153.
9. Zhou, S.; Koh, H. L.; Gao, Y.; Gong, Z. Y.; Lee, E. J. Bioactivation of herbal constituents: Simple alerts in the complex system. Life Sci. 2004, 74, 935-968.
10. Lin, J. H.; Lu, A. Y. H. Role of pharmacokinetics and metabolism in drug discovery and development. Pharmacol. Rev. 1997, 49, 403-449. (Pubitemid 28030947)
11. Hao, M.; Zhao, Y.; Chen, P.; Huang, H.; Liu, H.; Jiang, H.; Zhang, R.; Wang, H. Structure-activity relationship and substrate-dependent phenomena in effects of ginsenosides on activities of drug-metabolizing P450 enzymes. PLoS One 2008, 3, e2697.
12. Fang, Z. Z.; Zhang, Y. Y.; Ge, G. B.; Liang, S. C.; Sun, D. X.; Zhu, L. L.; Dong, P. P.; Cao, Y. F.; Yang, L. Identification of cytochrome P450 (CYP) isoforms involved in metabolism of corynoline and assessment of its herb-drug interaction. Phytother. Res. 2011, 25, 256-263.
13. Sun, D. X.; Fang, Z. Z.; Zhang, Y. Y.; Cao, Y. F.; Yang, L.; Yin, J. Inhibitory effects of curcumenol on human liver cytochrome P450 enzymes. Phytother. Res. 2010, 24, 1213-1216.
14. Quintieri, L.; Palatini, P.; Moro, S.; Floreani, M. Inhibition of cytochrome P450 2C8-mediated drug metabolism by the flavonoid diosmetin. Drug Metab. Pharmacokinet. 2011, 26, 559-568.
15. Miners, J. O.; Mackenzie, P. I. Drug glucuronidation in human. Pharmacol. Ther. 1991, 51, 347-369.
16. Kiang, T. K.; Ensom, M. H.; Chang, T. K. UDP-glucuronosyltransferases and clinical drug-drug interactions. Pharmacol. Ther. 2005, 106, 97-132. (Pubitemid 40386722)
17. Ritter, J. K. Roles of glucuronidation and UDP-glucuronosyltransferasesin xenobiotic bioactivation reactions. Chem. Biol. Interact. 2000, 129, 171-193. (Pubitemid 32061059)
18. Tukey, R. H.; Strassburg, C. P. Human UDP-glucuronosyltransferases: metabolism, expression, and disease. Annu. Rev. Pharmacol. Toxicol. 2000, 40, 581-616. (Pubitemid 30340694)
19. Dong, R. H.; Fang, Z. Z.; Zhu, L. L.; Liang, S. C.; Ge, G. B.; Yang, L.; Liu, Z. Y. Investigation of UDP-glucuronosyltransferases (UGT) inhibitory properties of carvacrol. Phytother. Res. 2012, 26, 86-90.
20. Tsoutsikos, P.; Miners, J. O.; Stapleton, A.; Thomas, A.; Sallustio, B. C.; Knights, K. M. Evidence that unsaturated fatty acids are potent inhibitors of renal UDP-glucuronosyltransferases (UGT): kinetic studies using human kidney cortical microsomes and recombinant UGT1A9 and UGT2B7. Biochem. Pharmacol. 2010, 65, 919-921.
21. Nishimura, Y.; Maeda, S.; Ikushiro, S.; Mackenzie, P. I.; Ishii, Y.; Yamada, H. Inhibitory effects of adenine nucleotides and related substances on UDP-glucuronosyltransferase: structure-effect relationships and evidence for an allosteric mechanism. Biochim. Biophys. Acta 2007, 1770, 1557-1566. (Pubitemid 47503557)
22. Bock, K. W.; Wiltfang, J.; Blume, R.; Ullrich, D.; Bircher, J. Paracetamol as a test drug to determine glucuronide formation in man. Effects of inducers and of smoking. Eur. J. Clin. Pharmacol. 1987, 31, 677-683. (Pubitemid 17020998)
23. Krishnaswamy, S.; Duan, S. X.; von Moltke, L. L.; Greenblatt, D. J.; Sudmeier, J. L.; Bachovchin, W. W.; Court, M. H. Serotonin (5-hydroxytryptamine) glucuronidation in vitro: Assay development, human liver microsome activities and species differences. Xenobiotica 2003, 33, 169-180. (Pubitemid 36237939)
24. Krishnaswamy, S.; Duan, S. X.; von Moltke, L. L.; Court, M. H. Validation of serotonin (5-hydroxtryptamine) as an in vitro substrate probe for human UDP-glucuronosyltransferase (UGT) 1A6. Drug. Metab. Dispos. 2003, 31, 133-139. (Pubitemid 36735267)
25. Uchaipichat, V.; Mackenzie, P. I.; Guo, X. H.; Gardner-Stephen, D.; Galetin, A.; Houston, J. B.; Miners, J. O. Human UDP-glucuronosyltransferases: Isoform selectivity and kinetics of 4-methylumbelliferone and 1-naphthol glucuronidation, effects of organic solvents, and inhibition by diclofenac and probenecid. Drug. Metab. Dispos. 2004, 32, 413-423. (Pubitemid 38420275)
26. Du, W.; Huang, H. Correlation analysis of secondary metabolites and environmental factors in Tripterygium wilfordii. Acta Bot. Sin. 2008, 25, 707-713.